LEXINGTON, Mass.--(BUSINESS WIRE)--Dec 10, 2012--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on T2Hemostasis, the first system capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument. The data were presented by researchers from the University of Pennsylvania at the 54 th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, GA. The study demonstrated that T2MR technology can be applied through the T2Hemostasis assay to rapidly and accurately measure changes in hemostasis across a range of conditions, from impaired hemostasis to hypercoagulable states.
“To date there have been few advances in the rapid and reliable assessment of both impaired hemostasis and hypercoagulable states due to limitations in the measurement of integrated clotting reactions directly in whole blood," said Douglas B. Cines, MD, Professor of Pathology and Laboratory Medicine and Director of the Special Coagulation Laboratory, Perelman School of Medicine-University of Pennsylvania. “The data presented at ASH demonstrate the first application of a single sensitive and clinically useful platform to rapidly measure accelerated as well as impaired hemostasis. These data strongly suggest that the T2MR could be a fast and accurate clinical platform for making these measurements.” “These new data demonstrate how T2Hemostasis is able to monitor several critical hemostasis measurements on a single instrument in just minutes,” said John McDonough, President and CEO, T2 Biosystems. “T2Hemostasis, together with other products in our pipeline, including T2Candida, demonstrates the breadth of our rapid and accurate direct detection platform, which, we believe, has the potential to fundamentally enhance the quality of diagnostics, drug development and hemostasis research.” The presentation, entitled “Miniaturized T2MR magnetic resonance system for analysis of hemostasis and detection of impaired and prothrombotic blood disorders”, was authored by D.B. Cines, T. Lebedeva, M.A. Kowalska, M. Poncz, L. Rauova, A. Cuker, J.W. Weisel, L. R. Skewis, W. Massefski, V. Papkov, E.C. Thayer and T.J. Lowery.
In this study, T2MR, or T2 Magnetic Resonance, was measured continuously over 20 minutes using blood samples from consenting healthy adult donors. A portable version of the T2MR provided a continuous report on the dynamically changing microscopic environment of water during coagulation of whole blood and reconstituted whole blood. Results were confirmed by standard platelet aggregometry. The results demonstrated the accuracy and utility of T2Hemosatsis in the study and diagnosis of a spectrum of disorders that range from impaired hemostasis to hypercoagulable states.
About T2 Biosystems T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company’s products detect molecular, hemostasis or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices. For more information, please visit www.t2biosystems.com.
Disclosure: Dr. Cines acknowledges that his lab was provided financial support by T2 Biosystems.CONTACT: MacDougall Biomedical Communications Chris Erdman, 781-235-3060 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS PENNSYLVANIA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES ONCOLOGY RESEARCH SCIENCE SOURCE: T2 Biosystems Copyright Business Wire 2012 PUB: 12/10/2012 09:00 AM/DISC: 12/10/2012 09:00 AM http://www.businesswire.com/news/home/20121210005093/